Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER
CBER Director Peter Marks says center will mobilize necessary resources to make sure these provisions are implemented; Marks also offered comments in opposition to 'right-to-try' legislation.
You may also be interested in...
Gottlieb: Lack Of Compromise On Right-To-Try Bill Is 'Interesting Lesson In Politics' For Stakeholders
In interview with the Pink Sheet, former US FDA commissioner Scott Gottlieb said that opposition to the modified House version of the right-to-try legislation ultimately led to the less favorable Senate bill becoming law.
CBER director said unlicensed stem cell clinics often report adverse events not made public, which is a concern under Right To Try.
As of mid-year 2018, there were more than 950 regenerative medicine therapies in clinical trials, of which more than 90 are in Phase III.